Physician profile
Mark S Tomich
NPI 1841700762
$1,399.12
in general payments reported to CMS, 2019-2025
19 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $397 · 2023: $439 · 2024: $45.02 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $162.65 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $140.94 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $51.94 | 2021-2022 | |
| Abbott Laboratories | $50.38 | 2022-2023 | Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $32.78 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $26.46 | 2022 | |
| Daiichi Sankyo INC. | $23.78 | 2025 | Injectafer |
| Lilly USA, LLC | $20.99 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $18.95 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.15 | 2022 | |
| Boston Scientific Corporation | $15.99 | 2025 | Watchman |
| Astrazeneca Pharmaceuticals LP | $15.77 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $15.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.80 | 2023 | Repatha, Otezla |
| Philips North America LLC | $14.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tomich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.